Market Overview
The RSV treatment market covers prophylactic interventions such as monoclonal antibodies and vaccines, alongside therapeutic options for managing active RSV infections in vulnerable populations. The market has experienced substantial growth following the 2023-2024 approvals of the first RSV vaccines for older adults and long-acting monoclonal antibodies for infant prophylaxis. Revenue is distributed across hospital pharmacies, retail pharmacies, and online distribution channels, with North America currently representing the largest regional market share.
- •Global market valued at approximately $1.84 billion in 2025, projected to reach $2.06 billion in 2026
- •Market categorized by drug class into prophylaxis (monoclonal antibodies, vaccines) and treatment (supportive care, antiviral therapies)
- •Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies
Growth Drivers
The aging global population, particularly adults over 60, represents the primary driver as RSV causes severe respiratory illness in elderly populations comparable to influenza. Regulatory approvals of RSV vaccines and monoclonal antibody prophylaxis have unlocked new revenue streams and expanded the addressable patient population. Rising healthcare expenditure, improved diagnostic capabilities, and growing awareness of RSV as a serious public health concern have further accelerated market adoption.
- •Approximately 3 million adults over 60 hospitalized annually with RSV in high-income countries
- •WHO expected to advise on RSV vaccine use for older adults in 2025-2026, potentially expanding immunization programs
- •High disease burden in infants driving demand for prophylactic monoclonal antibody treatments
Segmentation and Regional Analysis
The market is segmented by drug class into prophylaxis and treatment categories, with prophylactic products commanding the majority share due to high adoption of monoclonal antibodies and vaccines. By end-user, hospital pharmacies dominate due to the need for professional administration of biologics and vaccines, though retail and online channels are growing. Geographically, North America leads the market due to early vaccine approvals and high healthcare spending, while Europe and Asia-Pacific represent significant growth opportunities.
- •Seven major markets (7MM) valued at $1.5 billion in 2025, projected to reach $4.2 billion by 2036 at 9.71% CAGR
- •Monoclonal antibody prophylaxis segment experiencing rapid growth following infant and elderly product approvals
- •Asia-Pacific emerging as high-growth region due to expanding healthcare infrastructure and disease awareness
Trends and Outlook
What are the recent trends and outlook?
The market is shifting toward combination vaccines that protect against RSV, influenza, and COVID-19 simultaneously, potentially improving vaccination rates and reducing administration costs. Extended age indications and combination product approvals are expected to significantly expand the addressable market over the next five years. With WHO guidance expected in 2025-2026 and increasing global vaccination initiatives, the RSV treatment market is positioned for sustained double-digit growth through 2036.
- •Maternal vaccination trials advancing to protect infants during their first RSV season through passive immunity transfer
- •Combination vaccine development targeting RSV with other respiratory pathogens expected to reach market by 2028-2030
- •Global immunization programs and WHO recommendations anticipated to drive adoption in middle-income countries
Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.
Connect to an analyst →Market size and forecast are Claight Analysis, informed by public research and industry data. Historical years before 2025 and all forecast years are Claight estimates at the stated CAGR. Retrieved 2026.